Trial Profile
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Avitinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Avitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- 04 Apr 2018 Results (n=52) assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AC0010 published in the Journal of Thoracic Oncology
- 21 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 21 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.